Table 4.

Univariate and multivariate analysis of ZNF331 methylation status with disease-free survival (DFS) and overall survival (OS) in colorectal cancer patients

Clinical parameter	DFS				OS
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value
Age (< 60 vs. ≥ 60 years)	1.099 (0.604–1.999)	0.757			1.132 (0.622–2.058)	0.685
Gender (male vs female)	1.129 (0.603–2.114)	0.704			1.080 (0.577–2.023)	0.810
ZNF331 (methylation vs. unmethylation)	0.273 (0.115–0.648)	0.003**	0.279 (0.117–0.664)	0.004**	0.261 (0.110–0.620)	0.002**	0.271 (0.114–0.646)	0.003**
Tumor differentiation (moderate or well vs. poor)	0.467 (0.254–0.857)	0.014*	0.727 (0.392–1.347)	0.311	0.471 (0.257–0.863)	0.015*	0.736 (0.397–01.365)	0.331
TNM stage (I–II vs. III–IV)	0.139 (0.062–0.312)	0.000***	0.151 (0.066–0.345)	0.000***	0.147 (0.065–0.332)	0.000***	0.164 (0.072–0.375)	0.000***
Tumor size (< 5 vs. ≥ 5 cm)	0.798 (0.438–1.453)	0.461			0.812 (0.446–1.478)	0.495
Tumor location (left colon vs. right colon)	1.577 (0.810–3.072)	0.180			1.579 (0.811–3.075)	0.179
KRAS mutation (wide type vs. mutation)	0.797 (0.418–1.520)	0.491			0.810 (0.425–1.545)	0.522
BRAF 600E mutation (wide type vs. mutation)	0.488 (0.118–2.025)	0.323			0.396 (0.095–1.642)	0.202
CIMP (high vs. low)	1.155 (0.412–3.242)	0.784			1.138 (0.405–3.192)	0.806

*p < 0.05, **p < 0.01, ***p < 0.001